RxSight Class Action Lawsuit: Deadline to Join on Sept. 22, 2025.
ByAinvest
Saturday, Sep 20, 2025 9:22 am ET1min read
RXST--
The lawsuit alleges that during the class period, Defendants made materially false and/or misleading statements and/or failed to disclose significant issues affecting the company's business. Specifically, the complaint alleges that:
1. The company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization.
2. Defendants had overstated the demand for RxSight's products.
3. As a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.
4. Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Investors who wish to participate in the class action can contact Phillip Kim, Esq. at 866-767-3653 or [email protected] for more information. There is no cost to join the class action, and investors may be entitled to compensation without payment of out-of-pocket fees or costs through a contingency fee arrangement.
Rosen Law Firm reminds investors of RxSight securities purchased between May 7, 2024 and July 8, 2025 to join the class action by September 22, 2025. A lead plaintiff must be appointed by the court. Investors may be entitled to compensation without payment of out-of-pocket fees or costs through a contingency fee arrangement. Contact Phillip Kim, Esq. at 866-767-3653 or [email protected] for more information.
Investors who purchased shares of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025 are encouraged to join a securities fraud class action lawsuit. The deadline to participate is September 22, 2025, and a lead plaintiff must be appointed by the court.The lawsuit alleges that during the class period, Defendants made materially false and/or misleading statements and/or failed to disclose significant issues affecting the company's business. Specifically, the complaint alleges that:
1. The company was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization.
2. Defendants had overstated the demand for RxSight's products.
3. As a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.
4. Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Investors who wish to participate in the class action can contact Phillip Kim, Esq. at 866-767-3653 or [email protected] for more information. There is no cost to join the class action, and investors may be entitled to compensation without payment of out-of-pocket fees or costs through a contingency fee arrangement.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet